Cyntegrity Germany GmbH, a risk-based quality management pioneer, announces its partnership with a German pharma supply chain consortium formed by esteemed industry leaders Frankfurt University of Applied Sciences, Bayer AG, Boehringer Ingelheim, GEFCO Forwarding, and others.
Frankfurt – Cyntegrity, Germany’s market leading provider of intelligent risk-based quality management (RBQM) solutions to the Life Sciences industry, announced its participation in the ground-breaking pharma initiative MYTIGATE for risk-based supply chain as core development partner.
The growing globalization of drug manufacturing and distribution, the trend towards outsourcing and the volatile environmental conditions pose costly risk to the pharmaceutical supply chain. In response to these increasing complex challenges, current Good Distribution Practice (GDP) introduced the requirement for a risk-based approach to supply chain management with the goal of maintaining full transparency along the distribution lanes, securing product safety and quality. Consequently, the pharma supply chain industry expressed its need for reliable, intelligent IT systems that can prospectively risk-assess and visualize the risk dynamics of alternative distribution lanes.
“With Cyntegrity, we have a partner with excellent developers and experience in the field of validated risk analysis in clinical trials on our side, which makes our conceptual framework a digital reality, “ says Professor Yvonne Ziegler, Frankfurt UAS and project lead, and explains that the cooperation with Cyntegrity has proven to be very valuable already during the first development step of a suitable architectural proposal.
A high-profile consortium, bringing experts in pharma supply chain together, was formed under the direction of Frankfurt University of Applied Sciences with the financial support of the State of Hesse (HA Project No .: 555 / 17-37).
“We feel very honored to join the consortium in its exciting journey and enable big pharma to benefit from our technology. This leading-edge project is another step in our master plan to de-risk the complete bio-pharmaceutical footprint. From drug development to drug manufacturing, warehousing, transport and supply,” says Dr Artem Andrianov, CEO Cyntegrity. “Our experienced team has matured in one of the most heavily regulated environments, the clinical research industry. This background gives us the right skill set and attitude to further enhance our cloud systems with risk-based lane assessment analytics.”
The consortium enters new territory. So far, routine use of validated risk-management technology only exists in the financial industry. With the resulting intelligent cloud solution MYTIGATE time and temperature-controlled pharmaceutical transportation from producer to pharmacy will become transparent and, in the long-term, predictable with regards to safety, quality and cost.
Primary project partners: Frankfurt University of Applied Sciences, Cyntegrity Germany GmbH, RheinMain University of Applied Sciences, Fulda University of Applied Sciences, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG and GEFCO Forwarding Germany GmbH.
Cyntegrity is a leading RBQM technology pioneer, offering specialized cloud and SaaS solutions for efficient risk-based quality management and clinical research. Cyntegrity’s mission is to offer high-quality analytics that are more predictive than retrospective, and can integrate legacy knowledge with current, real-world data to reduce human-risk and optimize business operations. For more information, visit cyntegrity.com or contact Linda Bunschoten, CMO Cyntegrity, at firstname.lastname@example.org.